Vistin Pharma ASA (LTS:0RAM) Net Income (Continuing Operations): kr74.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
75 GF Score
Price kr20.20
GF Value kr25.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Net Income (Continuing Operations)?

Vistin Pharma ASA LTS:0RAM -0.49% 75 Net Income (Continuing Operations) is kr74.5 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 75/100 and a GF Value™ of kr25.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Vistin Pharma ASA's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was kr21.5 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was kr74.5 Mil.

Vistin Pharma ASA  (LTS:0RAM) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Vistin Pharma ASA Net Income (Continuing Operations) Related Terms

Vistin Pharma ASA Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Net Income (Continuing Operations) Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.87 -4.72 45.60 62.75 74.75

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.70 18.47 18.53 16.06 21.49
LTS:0RAM
75GF Score
Vistin Pharma ASA LTS:0RAM
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr74.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of kr74.5 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Net Income (Continuing Operations) of kr74.5 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Net Income (Continuing Operations) too high?
Vistin Pharma ASA's current Net Income (Continuing Operations) is kr74.5 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Net Income (Continuing Operations) compare to ZTS and UTHR?
Vistin Pharma ASA's Net Income (Continuing Operations) of kr74.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Net Income (Continuing Operations) is kr74.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.71, compared to a current price of kr20.20 — trading 21.4% below its estimated fair value. The current Net Income (Continuing Operations) is kr74.5 Mil. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Net Income (Continuing Operations) is kr74.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.20 is trading 21.4% below its estimated GF Value™ of kr25.71. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Net Income (Continuing Operations): kr74.5 Mil
  • GF Value™: kr25.71 vs. price of kr20.20 (21.4% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score

Get the complete analysis for LTS:0RAM

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.20
Price
kr25.71
GF Value